IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2012-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1238 |
Summary: | The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management. |
---|---|
ISSN: | 1560-4071 2618-7620 |